6533b85ffe1ef96bd12c265e
RESEARCH PRODUCT
Testosterone metabolism in benign prostatic hypertrophy: in vivo studies of gestonorone caproate and cyproterone acetate.
F. OrestanoJ. E. Altweinsubject
Malemedicine.medical_specialtyUrologyProstatic HyperplasiaMuscle hypertrophychemistry.chemical_compoundIn vivoInternal medicinemedicineHumansTestosteroneCyproteroneTestosteroneGestonorone caproateAgedClinical Trials as TopicTreatment regimenbusiness.industryProstateCyproterone acetateMetabolismLuteinizing HormoneMiddle AgedEndocrinologychemistryDihydrotestosteronebusinessGestonorone Caproatemedicine.drugdescription
Summary 18 patients with obstructive benign prostatic hypertrophy were studied. A 5-day treatment with gestonorone caproate (200 mg daily and 200 mg on alternate days) and cyproterone acetate (300 mg daily) suppressed the plasma LH and serum LH levels. Subsequently, H3-testosterone was injected intravenously and its elimination from plasma and uptake and metabolism in the BPH tissue studied. The elimination of total radioactivity and H3-testosterone from plasma was not altered after the 3 treatment regimens as compared to the control group. The uptake of total radioactivity into BPH tissue and its intraprostatic metabolism particularly to dihydrotestosterone was significantly suppressed in the patients with daily injections of gestonorone. Cyproterone acetate and gestonorone caproate on alternate days did not cause this effect. Supported by the Helmut Horten Foundation.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1976-12-01 | British journal of urology |